ArticleBMC cancer2026
Integrated analysis reveals GSTA1 as a prognostic biomarker in stage I lung adenocarcinoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPostoperative survival in early-stage lung adenocarcinoma (LUAD) remains heterogeneous. Reliable prognostic biomarkers are needed to refine recurrence-risk stratification and guide individualized care.
methodsWe integrated transcriptomic profiles from 274 stage I LUAD tumors and 637 normal lung tissues across three public datasets—Genotype-Tissue Expression (GTEx), The Cancer Genome Atlas (TCGA), and Gene Expression Omnibus (GEO)—to identify differentially expressed genes (DEGs) with functional enrichment analyses. Findings were validated in an independent institutional cohort of 226 resected early-stage LUADs using tissue microarrays (TMAs) and immunohistochemistry (IHC).
resultsNine upregulated genes were associated with improved recurrence-free survival (RFS) including glutathione S-transferase alpha 1 (GSTA1). A three-gene model (NQO1, EPHX1, and GSTA1) stratified patients into high- and low-risk groups. TMA analyses confirmed that higher tumor GSTA1 protein expression correlated with longer RFS. GSTA1 expression was also associated with key clinicopathologic features, including smoking history, presence of ground-glass opacity (GGO), pathological stage, and histologic subtype composition.
conclusionsHigh GSTA1 expression is associated with a favorable prognosis in stage I LUAD. Clinically, IHC-based GSTA1 scoring can be integrated into the postoperative workflow as a pragmatic risk-stratification aid: low GSTA1, especially when found alongside adverse features (micropapillary/solid patterns, STAS, or absent GGO), may warrant intensified surveillance and a lower threshold for adjuvant-therapy discussion, whereas high GSTA1 supports standard surveillance in otherwise low-risk profiles.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.